Effect of moxifloxacin combined with cephalosporin in the treatment of chronic bronchitis
莫西沙星联合头孢菌素抗菌药物治疗慢性支气管炎的效果

摘要

目的 实验将针对慢性支气管炎患者实施治疗，重点分析莫西沙星联合头孢菌素抗菌药物治疗，帮助患者达成理想的治疗结局，优化治疗方案。方法 针对80例慢性支气管炎患者为对象，样本来源于2021年6月至2022年6月前来的患者，按照时间划分两个对比组，对照组为头孢菌素抗菌药物治疗，观察组为莫西沙星联合头孢菌素抗菌药物治疗，对比治疗成果。结果 从数据可见，观察组患者在症状缓解时间中（咳嗽、呼吸困难、发热、肺部湿啰音）用时短于对照组，具有统计学意义（P＜0.05）。同时，在PaO2、PaCO2以及FeNO水平改善上，观察组血气指标水平均优于对照组，差异显著（P＜0.05）。此外，在患者的炎症因子水平对比中，观察组各个项目的数据优于对照组，对比差异大。最后，在总疗效观察组患者以95.0%高于对照组的77.5%，差异显著（P＜0.05）。结论 采用莫西沙星联合头孢菌素抗菌药物治疗对于慢性支气管炎患者，有助于改善患者的血气状况，有利于疾病转归，达成较好的治疗效果，值得推广。

Abstract

Objective This experiment will focus on the implementation of treatment for patients with chronic bronchitis, focusing on the analysis of moxifloxacin combined with cephalosporin antimicrobial therapy, to help patients achieve the ideal treatment outcome and optimize the treatment plan.
Methods A total of 80 patients with chronic bronchitis were selected as the object, and the samples were collected from patients before June 2021 to June 2022. According to the time, they were divided into two comparison groups. The control group was treated with cephalosporin antibiotics, and the observation group was treated with moxifloxacin combined with cepha- losporin antibiotics.
Results According to the data, the time of symptom relief (cough, dyspnea, fever, pulmonary moist rales) in the observation group was shorter than that in the control group, with statistical significance (P<0.05). At the same time, in the improvement of PaO2, PaCO2 and FeNO levels, the blood gas index levels of the observation group were better than those of the control group, and the differences were significant (P<0.05). In addition, in the comparison of the levels of inflammatory factors in patients, the data of each item in the observation group were better than those in the control group, and the comparison difference was large. Finally, the total efficacy of the observation group was 95.0% higher than that of the control group (77.5%), and the difference was significant (P<0.05).
Conclusion   The use of moxifloxacin combined with cephalosporin in the treatment of chronic bronchitis patients is helpful to improve the blood gas status of patients, is conducive to the disease outcome, achieve a good treatment effect, worthy of promotion.